کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2113116 | 1084443 | 2012 | 8 صفحه PDF | دانلود رایگان |
In this study, we investigated the synergistic effects of panobinostat and bortezomib on adriamycin-resistant HL60/ADR cells and refractory acute myelogenous leukemia (AML) primary cells. Combination of both agents had synergistic cytotoxicity on these cells, and increased the sensitivity of HL60/ADR cells to adriamycin. Panobinostat plus bortezomib was shown to modulate multiple apoptotic and drug metabolic related molecules, including activation of caspases, down-regulation of XIAP, Bcl-2 and MRP1. These effects were likely to be mediated via inhibition of AKT and NF-κB pathways. These findings provide evidence for clinic protocols using panobinostat and borezomib to overcome drug resistance in refractory AML patients.
► We detected that panobinostat and bortezomib had synergistic effects on chemoresistant AML cells.
► The agents in combination increased the sensitivity of HL60/ADR cells to adriamycin.
► We demonstrated that the combined treatment induced apoptosis and drug metabolism.
► These effects were likely to be mediated via inhibition of AKT and NF-κB pathways.
Journal: Cancer Letters - Volume 326, Issue 2, 30 December 2012, Pages 135–142